in which X, Y and Z are, independently, hydrogen, halogen, hydroxy,nitro, cyano, carboxyl, trifluoromethyl, phenyl, amino, alkylamino, dialkylamino, alkyl or alkoxy; R₁ is alkyl, alkenyl, cycloalkyl, phenyl, benzyl or substituted phenyl or benzyl, R₂ is
or a pharmaceutically acceptable salt thereof, are ACAT inhibitors.
摘要:
The invention concerns compounds of the formula: wherein R is mono- or dihalo, amino, nitro, cyano, hydroxy, trifluoromethyl, mercapto, lower alkyl, lower alkoxy, alkanoyl, cycloalkyl of 5-7 carbon atoms, carboxy, alkoxycarbonyl, mono- or di-lower alkyl substituted amino, alkanoylamino, lower alkyl thio, lower alkylsulfonyl, sulfamoyl, lower alkyl substituted sulfamoyl, phenyl or phenyl substituted with halo, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, amino, cyano or nitro. and A is amine selected from wherein R 1 is hydrogen or R 2 CH 2 wherein R 2 is mono- or diloweralkylamino, mono- or di-N-lower alkylaminoloweral- kyl, (2-furyl)methylamino, benzylamino, lowercycloalkylamino, 1-pyrrolidinyl, 1-piperidinyl, 1-hexahydroazepinyl, 1-octahydroazocinyl, 3-thiazolidinyl, 4-morpholinyl or 4-thiomorpholinyl; R 3 is hydrogen or (1-piperidinyl)methyl with the proviso that when R 3 is (1-piperidinyl)methyl, R 1 is hydrogen; n is 1 to 4 and the pharmacologically acceptable salts thereof; which inhibit gastric acid secretion. Processes for preparing the compounds and pharmaceutical compositions containing them are also disclosed.
摘要:
The invention concerns compounds of the formula: wherein R is mono- or dihalo, amino, nitro, cyano, hydroxy, trifluoromethyl, mercapto, lower alkyl, lower alkoxy, alkanoyl, cycloalkyl of 5-7 carbon atoms, carboxy, alkoxycarbonyl, mono- or di-lower alkyl substituted amino, alkanoylamino, lower alkyl thio, lower alkylsulfonyl, sulfamoyl, lower alkyl substituted sulfamoyl, phenyl or phenyl substituted with halo, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, amino, cyano or nitro. and A is amine selected from
wherein R 1 is hydrogen or R 2 CH 2 wherein R 2 is mono- or diloweralkylamino, mono- or di-N-lower alkylaminoloweral- kyl, (2-furyl)methylamino, benzylamino, lowercycloalkylamino, 1-pyrrolidinyl, 1-piperidinyl, 1-hexahydroazepinyl, 1-octahydroazocinyl, 3-thiazolidinyl, 4-morpholinyl or 4-thiomorpholinyl; R 3 is hydrogen or (1-piperidinyl)methyl with the proviso that when R 3 is (1-piperidinyl)methyl, R 1 is hydrogen; n is 1 to 4 and the pharmacologically acceptable salts thereof; which inhibit gastric acid secretion. Processes for preparing the compounds and pharmaceutical compositions containing them are also disclosed.
in which X, and Y are, independently, hydrogen, halogen, hydroxy, nitro, cyano, carboxyl, trifluoromethyl, phenyl, amino, alkylamino, dialkylamino, alkyl, alkoxy or phenylalkyloxy; R₁ is hydrogen, alkyl, hydroxyalkyl, alkenyl, cycloalkyl, phenylcycloalkyl, 1-hydroxymethylphenethyl, 1-(t-butyl)dimethylsilyloxymethylphenethyl, 1-(t-butyl)dimenthylsilyloxy methylisopentyl, 1-hydroxymethylisopentyl, phenyl, benzyl or substituted phenyl or benzyl, where the substituents are alkyl, alkoxy, halogen, cyano, trifluoromethyl, amino, alkylamino, dialkylamino, nitro or phenyl, benzyl, phenethyl or R₁ is thienyl, imidazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, benzamidazolyl, phenylalkylpiperidinyl or morpholino; R₂ is alkyl, cycloalkyl, phenyl, benzyl or substituted phenyl or benzyl in which said substituent is alkyl, alkoxy, halogen, cyano, trifluoromethyl amino, nitro, alkylamino or dialkylamino; and a pharmaceutically acceptable salt thereof; are ACAT inhibitors, some of which possess antioxidant properties.
摘要:
The invention describes compounds of formula (I)
or tautomer thereof, wherein R¹, R², R³, R⁴ and R⁵ are independently selected from hydrogen, lower alkyl containing 1 to 6 carbon atoms, hydroxy, lower alkyloxy containing 1 to 6 carbon atoms, halogen, trifluoromethyl, trifluoromethoxy, nitro, cyano, phenoxy, benzyloxy, acetamido -S(O) p -CH₃ or any two adjacent groups are joined to form methylenedioxy; m is 0 to 2; n is 1 to 3; p is 0 to 2, and pharmaceutically acceptable salts and hydrates thereof which are useful as antiosteoporotic agents
摘要:
The invention concerns compounds of the formula wherein B is a moiety having the formula: the dotted line represents a bond which is present when B is formula Id or If and absent when B isformula le, R is hydrogen, mono- or dihalo, amino, nitro, cyano, hydroxy, trifluoromethyl, mercapto, lower alkyl, lower alkoxy, alkanoyl, lowercycloalkyl, carboxy, alkoxycarbonyl, mono- or di-lower alkyl substituted amino, alkamoylamino, lower alkyl thio, loweralkyl-sulfonyl, sulfamoyl, lower alkyl substituted sulfamoyl, phenyl or phenyl substituted with halo, lower alkyl, lower alkoxy,trifluoromethyl, hydroxy, amino, cyano or nitro; X is SO 2 , SO, S or C=O and A is an amine of formula:
wherein n is 1 to 4; R' is hydrogen or R 2 CH2 wherein R 2 is mono- or diloweralkylamino, mono- or di-N-lower- alkylamino lower alkyl, (2-furyl)methylamino, benzylamino, lower cycloalkylamino of 5 to 7 carbon atoms, 1-pyrrolidinyl, 1-piperidinyl, 1-hexahydroazepinyl, 1-octahydroazocinyl, 3-thiazolidinyl,4-morpholinyl or4-thiomorpholinyl; R 3 is hydrogen or (1-piperidinyl)-methyl with the proviso that when R 3 is (1-piperidinyl)-methyl, then R' is hydrogen; and the pharmacologically acceptable salts thereof which inhibit gastic acid secretion. Processes for preparing the compounds and pharmaceutical compositions containing them are also disclosed.